Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978340 | 0.85 | EGFR (0.42) | EGFRERBB2ALDH1A1SMN1; SMN2CA2 | |
| SCHEMBL3975862 | 0.78 | PLA2G10 (0.53) | EGFRERBB2PLA2G10PLA2G2AALDH1A1 | |
| SCHEMBL3975403 | 0.73 | EGFR (0.69) | EGFRERBB2PLA2G10PLA2G2A | |
| SCHEMBL3972176 | 0.72 | EGFR (0.60) | EGFRERBB2 | |
| SCHEMBL3977341 | 0.72 | CA1 (0.48) | EGFRERBB2PLA2G10PLA2G2AALDH1A1 | |
| SCHEMBL2635907 | 0.72 | HDAC6 (0.59) | PLA2G10PLA2G2ASMN1; SMN2CCNA2CDK2 | |
| SCHEMBL7973254 | 0.72 | PLK1 (0.56) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL30572295 | 0.71 | PLA2G10 (0.48) | PLA2G10PLA2G2AALDH1A1SMN1; SMN2PARP10 | |
| SCHEMBL17127693 | 0.70 | EGFR (0.66) | EGFRERBB2KDM4E | |
| SCHEMBL3973361 | 0.70 | EGFR (0.52) | EGFRERBB2PLA2G10PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569602-B2 | Furan derivatives as EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-1673360-B1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1673360-A1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005037812-A1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER3, NR4A3 | EGFR 433/4885ERBB2 854/4885PLA2G10 1590/4885 |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | PTGER4, PTGER3, NR4A3 | EGFR 564/4885ERBB2 1166/4885PLA2G10 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.